Erratum: Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant staphylococcus aureus with a range of vancomycin mics in a murine pneumonia model (Antimicrobial Agents and Chemotherapy (2010) 54:12 (5115-5119) DOI: 10.1128/AAC.00062-10);Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5115-5119

  Crandon, Jared L ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; LINEZOLID; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE;

EID: 78649682544     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01878-21     Document Type: Erratum

References (33)

1. Albrecht, L. M., M. J. Rybak, L. H. Warbasse, and D. J. Edwards. 1991. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 25:713-715.
2. American Thoracic Society. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
3. Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1):16-23.
4. Berthoin, K., E. Ampe, P. M. Tulkens, and S. Carryn. 2009. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int. J. Antimicrob. Agents 34:555-560.
5. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.
6. Clinical Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI publication M07-A8. CLSI, Wayne, PA.
7. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:2383-2388.
8. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62:116-121.
9. Healy, D. P., R. E. Polk, M. L. Garson, D. T. Rock, and T. J. Comstock. 1987. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob. Agents Chemother. 31:393-397.
10. Hegde, S. S., S. Difuntorum, R. Skinner, J. Trumbull, and K. M. Krause. 2009. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J. Antimicrob. Chemother. 63:763-766.
11. Hegde, S. S., N. Reyes, R. Skinner, and S. Difuntorum. 2008. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J. Antimicrob. Chemother. 61:169-172.
12. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155.
13. Kaatz, G. W., S. L. Barriere, D. R. Schaberg, and R. Fekety. 1987. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 31:527-530.
14. Knudsen, J. D., K. Fuursted, F. Espersen, and N. Frimodt-Moller. 1997. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob. Agents Chemother. 41:1910-1915.
15. Kollef, M. H., J. Rello, S. K. Cammarata, R. V. Croos-Dabrera, and R. G. Wunderink. 2004. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30:388-394.
16. Koomanachai, P., J. L. Crandon, M. A. Banevicius, L. Peng, and D. P. Nicolau. 2009. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob. Agents Chemother. 53:5060-5063.
17. Kosowska-Shick, K., C. Clark, G. A. Pankuch, P. McGhee, B. Dewasse, L. Beachel, and P. C. Appelbaum. 2009. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53:4217-4224.
18. Krause, K. M., M. Renelli, S. Difuntorum, T. X. Wu, D. V. Debabov, and B. M. Benton. 2008. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 52:2647-2652.
19. Laohavaleeson, S., P. R. Tessier, and D. P. Nicolau. 2008. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob. Agents Chemother. 52:2389-2394.
20. LaPlante, K. L., S. N. Leonard, D. R. Andes, W. A. Craig, and M. J. Rybak. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob. Agents Chemother. 52:2156-2162.
21. Liu, C., and H. F. Chambers. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47:3040-3045.
22. Lynch, J. P., III. 2001. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 119:373S-384S.
23. Merrikin, D. J., J. Briant, and G. N. Rolinson. 1983. Effect of protein binding on antibiotic activity in vivo. J. Antimicrob. Chemother. 11:233-238.
24. Moise, P. A., A. Forrest, S. M. Bhavnani, M. C. Birmingham, and J. J. Schentag. 2000. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am. J. Health Syst. Pharm. 57(Suppl. 2):S4-S9.
25. Moise, P. A., and J. J. Schentag. 2000. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int. J. Antimicrob. Agents 16(Suppl. 1):S31-S34.
26. Nicolau, D. P., H. M. Mattoes, M. Banevicius, D. Xuan, and C. H. Nightingale. 2003. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob. Agents Chemother. 47:1630-1635.
27. NNIS System. 2004. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32:470-485.
28. Reyes, N., R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P. Obedencio, A. Gough, M. Conner, and S. S. Hegde. 2005. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:4344-4346.
29. Rybak, M. J., B. M. Lomaestro, J. C. Rotschafer, R. C. Moellering, Jr., W. A. Craig, M. Billeter, J. R. Dalovisio, and D. P. Levine. 2009. Therapeutic monitoring of vancomycin in adults. Summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29:1275-1279.
30. Sakoulas, G., G. M. Eliopoulos, R. C. Moellering, Jr., C. Wennersten, L. Venkataraman, R. P. Novick, and H. S. Gold. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502.
31. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
32. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin- susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794. (Pubitemid 47434257)
33. Vincent, J. L., J. Rello, J. Marshall, E. Silva, A. Anzueto, C. D. Martin, R. Moreno, J. Lipman, C. Gomersall, Y. Sakr, and K. Reinhart. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323-2329.